First phase II/III trial to verify the efficacy and safety of trifluridine/tipiracil plus bevacizumab as second-line treatment for patients with metastatic colorectal cancer
Contributors: Yasutoshi Kuboki and Takayuki Yoshino;
Department of Experimental Therapeutics and Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan
Advancing human and canine cancer care: analysis of the largest clinico-genomics canine cancer dataset as a hypothesis generation for cancer drug discovery
AI analysis of canine clinical and genomic data including treatment with targeted therapies can provide translational insights and help accelerate drug development and repurposing to improve cancer outcomes.
Unusual PDGFRB fusion reveals novel mechanism of kinase activation in Ph-like B-ALL
The detailed functional study of rare and unusual genomic events in patient cancer samples can provide some unique and important biological insights. We have uncovered a novel mechanism of tyrosine kinase activation in a form of leukaemia in which tyrosine kinase activation is the hallmark.
